These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12677780)

  • 21. [The chronic renal failure epidemic: an underestimated public health problem].
    Zoccali C; Caridi G; Cambareri F
    G Ital Nefrol; 2007; 24 Suppl 38():3-7. PubMed ID: 17922440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment.
    Locatelli F; Bommer J; London GM; Martín-Malo A; Wanner C; Yaqoob M; Zoccali C
    Nephrol Dial Transplant; 2001 Mar; 16(3):459-68. PubMed ID: 11239016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging cardiovascular risk factors in end-stage renal disease.
    Yaqoob MM
    J Nephrol; 2002; 15(2):205-8. PubMed ID: 12018642
    [No Abstract]   [Full Text] [Related]  

  • 25. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
    Chi YW; Jaff MR
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renal markers and predictors, and renal and cardiovascular risk factors].
    Fernández-Andrade C
    Nefrologia; 2002; 22 Suppl 1():2-29. PubMed ID: 11987667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of chronic inflammation in cardiovascular mortality of uremic patients.
    Panichi V; Taccola D; Migliori M; Consani C; Giovannini L; Tetta C
    Int J Artif Organs; 2003 Jan; 26(1):12-8. PubMed ID: 12602464
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiovascular consequences of sleep apnea].
    Foucher A
    Nephrol Ther; 2007 Dec; 3(7):463-73. PubMed ID: 18048002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiovascular risk and renal transplantation].
    Stallone G; Infante B; Schena A; Di Paolo S; Grandaliano G; Gesualdo L; Schena FP
    G Ital Nefrol; 2004; 21(2):144-55. PubMed ID: 15351949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classical and "non-classical" cardiovascular risk factors in Tunisian patients with end stage renal disease: prevalence and association with cardiovascular events.
    Fellah H; Feki M; Feki H; Souissi M; Kaabachi N; Ben Abdallah T; Massy ZA; Ben Maiz H; Lacour B; Mebazaa A
    Clin Lab; 2004; 50(7-8):447-53. PubMed ID: 15330514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardiovascular disease in terminal end-stage renal failure--epidemiological aspects].
    Kessler M
    Nephrologie; 2002; 23(7):361-5. PubMed ID: 12500422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for cardiovascular disease in pediatric renal transplant recipients.
    Silverstein DM
    Pediatr Transplant; 2004 Aug; 8(4):386-93. PubMed ID: 15265167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.
    Mallamaci F; Tripepi G; Cutrupi S; Malatino LS; Zoccali C
    Kidney Int; 2005 Jun; 67(6):2330-7. PubMed ID: 15882276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS) play a role in nocturnal hypertension and increased cardiovascular risk of renally impaired patients?
    Portaluppi F; Cortelli P; Buonaura GC; Smolensky MH; Fabbian F
    Chronobiol Int; 2009 Aug; 26(6):1206-21. PubMed ID: 19731113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.